These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 15598980

  • 1. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM.
    J Clin Oncol; 2004 Dec 15; 22(24):4951-7. PubMed ID: 15598980
    [Abstract] [Full Text] [Related]

  • 2. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    Rondanina G, Puntoni M, Severi G, Varricchio C, Zunino A, Feroce I, Bonanni B, Decensi A.
    J Clin Oncol; 2008 Mar 20; 26(9):1537-43. PubMed ID: 18349406
    [Abstract] [Full Text] [Related]

  • 3. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.
    Cancer; 2005 May 15; 103(10):1996-2005. PubMed ID: 15825209
    [Abstract] [Full Text] [Related]

  • 4. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making.
    Matloff ET, Moyer A, Shannon KM, Niendorf KB, Col NF.
    J Womens Health (Larchmt); 2006 Sep 15; 15(7):843-56. PubMed ID: 16999640
    [Abstract] [Full Text] [Related]

  • 5. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    McKay A, Latosinsky S, Martin W.
    Cancer; 2005 Jan 01; 103(1):209-10. PubMed ID: 15540238
    [No Abstract] [Full Text] [Related]

  • 6. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD.
    J Clin Oncol; 2003 Dec 01; 21(23):4322-8. PubMed ID: 14645421
    [Abstract] [Full Text] [Related]

  • 7. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.
    Cancer Epidemiol Biomarkers Prev; 2007 May 01; 16(5):1032-4. PubMed ID: 17507634
    [Abstract] [Full Text] [Related]

  • 8. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial.
    Kinney AY, Richards C, Vernon SW, Vogel VG.
    Prev Med; 1998 May 01; 27(5 Pt 1):713-9. PubMed ID: 9808803
    [Abstract] [Full Text] [Related]

  • 9. Chemoprevention of breast cancer for women at high risk.
    Chan K, Morris GJ.
    Semin Oncol; 2006 Dec 01; 33(6):642-6. PubMed ID: 17145342
    [Abstract] [Full Text] [Related]

  • 10. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.
    J Natl Cancer Inst; 2005 Nov 16; 97(22):1652-62. PubMed ID: 16288118
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
    Ozanne EM, Esserman LJ.
    Cancer Epidemiol Biomarkers Prev; 2004 Dec 16; 13(12):2043-52. PubMed ID: 15598759
    [Abstract] [Full Text] [Related]

  • 12. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
    Layeequr Rahman R, Crawford S.
    Breast; 2009 Oct 16; 18(5):289-93. PubMed ID: 19716702
    [Abstract] [Full Text] [Related]

  • 13. Women's decision making about whether or not to use breast cancer chemoprevention.
    Altschuler A, Somkin CP.
    Women Health; 2005 Oct 16; 41(2):81-95. PubMed ID: 16219589
    [Abstract] [Full Text] [Related]

  • 14. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M.
    Cancer; 2004 May 01; 100(9):1800-6. PubMed ID: 15112259
    [Abstract] [Full Text] [Related]

  • 15. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer.
    Watson M, Lloyd S, Davidson J, Meyer L, Eeles R, Ebbs S, Murday V.
    Br J Cancer; 1999 Feb 01; 79(5-6):868-74. PubMed ID: 10070883
    [Abstract] [Full Text] [Related]

  • 16. Choices in cancer treatment: a qualitative study of the older women's (>70 years) perspective.
    Husain LS, Collins K, Reed M, Wyld L.
    Psychooncology; 2008 Apr 01; 17(4):410-6. PubMed ID: 17847124
    [Abstract] [Full Text] [Related]

  • 17. [Breast cancer chemoprevention. Rational, trials results and future].
    Cutuli B, Lesur A, Namer M, Kerbrat P.
    Bull Cancer; 2009 May 01; 96(5):519-30. PubMed ID: 19467983
    [Abstract] [Full Text] [Related]

  • 18. How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide.
    McKay A, Martin W, Latosinsky S.
    Breast Cancer Res Treat; 2005 Nov 01; 94(2):153-9. PubMed ID: 16261414
    [Abstract] [Full Text] [Related]

  • 19. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J, Birch S, Slee C, McCarthy TJ, Helms LJ, Kuppermann M.
    Med Care; 2008 Sep 01; 46(9):946-53. PubMed ID: 18725849
    [Abstract] [Full Text] [Related]

  • 20. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
    Brewster AM, Christo DK, Lai H, Helzlsouer K.
    Cancer; 2005 Mar 15; 103(6):1147-53. PubMed ID: 15674856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.